

1 This unedited manuscript has been accepted for future
2 publication. The manuscript will undergo copyediting,
3 typesetting, and galley review before final publication. Please note
4 that this advanced version may differ from the final version.









6 CASE STUDIES

8 **Characterization of bone marrow aspirate reports in dogs and** 9 **cats: A retrospective study**

11 *Caracterización de informes de aspirado de médula ósea en perros y gatos: un estudio*
12 *retrospectivo*

14 *Caracterização de laudos de aspirados de medula óssea em cães e gatos: estudo*
15 *retrospectivo*

17 Ingrid J Roldán-Carvajal^{1*} ; David Alzate-Velásquez² ; Julián D Muñoz-Duque³ ; Andrés F Mesa-
18 Oquendo⁴ ; Jorge E Salazar-Flórez⁵ ; Patricia E Jaramillo-Arbeláez¹ 

20 ¹ Grupo de Investigación HEMO, Escuela de Microbiología, Universidad de Antioquia. Medellín, Colombia.

21 ² Clínica Veterinaria Caninos y Felinos. Medellín, Colombia.

22 ³ Grupo de Investigación en Patobiología QUIRÓN, Facultad de Ciencias Agrarias, Universidad de Antioquia. Medellín, Colombia.

23 ⁴ Universidad CES, Medellín, Colombia.

24 ⁵ Fundación Universitaria San Martín, Sede Sabaneta, Colombia.

Received: August 16, 2024. Accepted: November 8, 2024

*Corresponding author: Calle 67 No. 53-108, Bloque 5, Medellín, Colombia. Email: ingrid.roldan@udea.edu.co



This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License, which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

© 2024 Universidad de Antioquia. Published by Universidad de Antioquia, Colombia.

eISSN: 2256-2958

Rev Colomb Cienc Pecu

<https://doi.org/10.17533/udea.rccp.v38n2a9>

25 *To cite this article:*

26 Roldán-Carvajal IJ, Alzate-Velásquez D, Muñoz-Duque JD, Mesa-Oquendo AF, Salazar-Flórez JE, Jaramillo-
27 Arbeláez PE. Characterization of bone marrow aspirate reports in dogs and cats: A retrospective study. Rev
28 Colomb Cienc Pecu. Year, Vol, number, and pages pending. DOI: <https://doi.org/10.17533/udea.rccp.v38n2a9>

29

30 **Abstract**

31 **Background:** Bone Marrow Aspirate (BMA) allows the study, staging, and monitoring of
32 multiple conditions with bone marrow involvement. The BMA report is a crucial component
33 of the post-analytical stage and significantly influences the veterinarian's understanding and
34 decision-making process. **Objective:** To describe the zoographic, clinical, and quality
35 characteristics of BMA reports, as well as the frequency of diagnoses and associated factors in
36 dogs and cats treated at veterinary centers in Colombia from 2012 to 2023. **Methods:** This was
37 a cross-sectional descriptive study. Data on zoographic and clinical variables were extracted
38 from BMA reports and consultations; the frequency of diagnoses and associated factors were
39 determined. Adherence to reporting quality was evaluated using established guidelines for
40 BMA in dogs, cats, and humans. **Results:** A total of 135 BMA reports were reviewed from
41 eight veterinary institutions: 116 for dogs and 19 for cats, with a mean age of 5.22 ± 3 years;
42 53% were males. The most common indication for BMA was anemia, alone or with other
43 abnormalities. The least adhered-to reporting elements were puncture site (91.9%), relevant
44 clinical data (85.2%), and morphological evaluation by cell line (52.6%). Additionally, 27.4%
45 of the reports were excluded due to poor sample quality. The most frequent diagnosis in dogs
46 was hypoplasia (36.1%), while in cats, it was neoplasia (40.0%). Erythroid hyperplasia and
47 neoplasms were more prevalent in males, whereas granulocytic hypoplasia was more common
48 in females. **Conclusions:** BMA as a diagnostic tool in dogs and cats in Colombia is rare. A
49 significant proportion of samples did not meet quality criteria, and there was low adherence to
50 reporting guidelines.

51 **Keywords:** *bone marrow; bone marrow aspirate; cat diseases; dog diseases; hematology;*
52 *hyperplasia; neoplasms; pets.*

53 **Resumen**

54 **Antecedentes:** El aspirado de médula ósea permite el estudio, estadificación y seguimiento de
55 múltiples entidades con compromiso medular; el informe es un componente esencial de la etapa

56 posanalítica y los ítems establecidos por cada institución influyen significativamente en la
57 comprensión y toma de decisiones por parte del médico tratante. **Objetivo:** Describir
58 características zoográficas, clínicas y de calidad, así como la frecuencia de diagnósticos y sus
59 factores asociados en informes de aspirado de médula ósea de caninos y felinos atendidos en
60 centros veterinarios de Colombia durante el período 2012-2023. **Métodos:** Estudio descriptivo
61 transversal. A partir de los informes de aspirado de médula ósea e interconsultas, se extrajeron
62 variables zoográficas, clínicas y se determinó la frecuencia de diagnósticos y factores asociados
63 a estos. Se evaluó la adherencia al reporte de variables de calidad contrastando con directrices
64 para el reporte de aspirados de médula ósea en caninos, felinos y humanos. **Resultados:** A
65 partir de 8 instituciones veterinarias, se obtuvieron 135 informes de aspirado de médula ósea,
66 116 caninos y 19 felinos, con una edad promedio de 5.22 ± 3 años, el 53% fueron machos; la
67 indicación más frecuente fue anemia persistente sola o acompañada de otra alteración. Los
68 ítems con menor adherencia en el reporte de resultados fueron sitio de punción (91.9%), datos
69 clínicos relevantes (85.2%) y valoración morfológica por línea (52.6%). El 27.4% de los
70 informes fue excluido por causas asociadas a la calidad de la muestra. El diagnóstico más
71 común en caninos fue hipoplasia (36.1%) y en felinos neoplasia (40.0%); la hiperplasia
72 eritroide y las neoplasias fueron más comunes en machos, en tanto que la hipoplasia
73 granulocítica fue más frecuente en hembras. **Conclusiones:** El estudio de médula ósea como
74 herramienta diagnóstica en caninos y felinos atendidos en Colombia es poco frecuente. Se
75 encontró un porcentaje significativo de muestras que no cumplían con criterios de calidad y
76 baja adherencia a las guías para el reporte de resultados.

77 **Palabras clave:** *aspirados de médula ósea; enfermedades de los gatos; enfermedades de los*
78 *perros; hematología; hiperplasia; mascotas; médula ósea; neoplasias.*

79 **Resumo**

80 **Antecedentes:** A aspiração da medula óssea permite o estudo, estadiamento e monitorização
81 de múltiplas entidades com envolvimento medular; O laudo é componente essencial da etapa
82 posanalítica e os itens estabelecidos por cada instituição influenciam significativamente o
83 entendimento e a tomada de decisão do médico assistente. **Objetivo:** Descrever as
84 características zoográficas, clínicas e de qualidade, bem como a frequência dos diagnósticos e
85 seus fatores associados nos relatos de aspirados de medula óssea de cães e gatos atendidos em
86 centros veterinários na Colômbia durante o período 2012-2023. **Métodos:** Estudo descritivo
87 transversal. Dos laudos de aspirados de medula óssea e das interconsultas, foram extraídas

88 variáveis zoológicas e clínicas e determinadas a frequência dos diagnósticos e os fatores
89 associados a eles. A adesão às variáveis de qualidade do relato foi avaliada por meio de
90 diretrizes contrastantes para o relato de aspirados de medula óssea em cães, gatos e humanos.
91 **Resultados:** De 8 instituições veterinárias foram obtidos 135 laudos de aspirados de medula
92 óssea, 116 cães e 19 gatos, com idade média de $5,22 \pm 3$ anos, 53% eram do sexo masculino;
93 A indicação mais frequente foi anemia persistente isolada ou acompanhada de outra alteração.
94 Os itens com menor adesão na notificação dos resultados foram locais da punção (91,9%),
95 dados clínicos relevantes (85,2%) e avaliação morfológica por linha (52,6%). 27,4% dos laudos
96 foram excluídos por motivos associados à qualidade da amostra. O diagnóstico mais comum
97 em cães foi hipoplasia (36,1%) e em gatos neoplasia (40,0%); A hiperplasia e a neoplasia
98 eritróide foram mais comuns nos homens, enquanto a hipoplasia granulocítica foi mais comum
99 nas mulheres. **Conclusões:** O estudo da medula óssea como ferramenta diagnóstica em cães e
100 gatos tratados na Colômbia é raro. Foi encontrada uma porcentagem significativa de amostras
101 que não atendiam aos critérios de qualidade e baixa adesão às diretrizes para reporte de
102 resultados.

103 **Palavras-chave:** *animais de estimação; aspirados de medula óssea; doenças do cão, doenças*
104 *do gato; hematologia; hiperplasia; medula óssea; neoplasias.*

105 **Introduction**

106 Bone Marrow Aspirate (BMA) is an essential tool for studying, staging, and monitoring various
107 conditions involving the bone marrow (Javinsky, 2012; Stacy and Harvey, 2017). This
108 technique offers accurate diagnoses and is relatively safe, with minimal risks and few
109 complications (Woods *et al.*, 2021). The effective use of BMA in routine veterinary practice
110 requires proper sample collection, precise smear interpretation, and comprehensive reporting
111 that provides clear diagnostic information (Messick, 2023).

112 The BMA report is a crucial component of the post-analytical stage and significantly influences
113 the veterinarian's understanding and decision-making process (Hawkins, 2012; Sciacovelli *et*
114 *al.*, 2016). A thorough report must include all elements for sample traceability, patient
115 identification, correlation with complete blood count, and clinical signs or prior studies. It
116 should also compare findings with reference values and, where appropriate, suggest further
117 tests such as immunophenotyping, cytochemistry, cytogenetics, and molecular biology. These

118 comprehensive reports help veterinarians make differential diagnoses and better understand the
119 findings (Stacy and Harvey, 2017).

120 Advancements in human and veterinary hematology have prompted the development of
121 guidelines aimed at standardizing processes from test requests to result reporting (Riley *et al.*,
122 2021; Ritt, 2022). In veterinary medicine, these guidelines frequently draw from human
123 models, leveraging physiological similarities across species like dogs, cats, and humans
124 (Comazzi *et al.*, 2017; Rütgen *et al.*, 2022).

125 In Colombia, there is a limited availability of publications on this topic, which has led to the
126 oversight of important aspects regarding the use of BMA in the dog and cat populations, which
127 numbered over eleven million in 2022 (Ministerio de Salud y Protección Social, 2022).

128 The aim of the present study was to describe the zoographic, clinical, and quality characteristics
129 of BMA reports, as well as the frequency of diagnoses and associated factors in dogs and cats
130 treated in veterinary centers in Colombia from 2012 to 2023.

131 **Materials and methods**

132 *Ethical considerations*

133 This study was approved by the Animal Experimentation Ethics Committee of the University
134 of Antioquia (Act 146 of 2022).

135 *Study design*

136 A descriptive cross-sectional study was conducted using convenience sampling of veterinary
137 medical centers and laboratories from various municipalities in Colombia. The study focused
138 on collecting BMA reports for dogs and cats from January 2012 to October 2023.

139 *Description of Reports*

140 The zoographic, clinical, and quality characteristics of the BMA reports were described using
141 univariate statistical analysis. Qualitative variables were assessed through relative and absolute
142 frequencies, while measures of central tendency and dispersion were applied to quantitative
143 variables.

144 Four age groups were defined based on the American Animal Hospital Association guidelines.
145 For cats: kitten (0-1-year-old), young adult (1-6-year-old), mature adult (7-10-year-old), and
146 senior (>10-year-old). For dogs: puppy (0-1-year-old), adult (1-6-year-old), senior (7-11-year-
147 old), and geriatric (>12-year-old) (Creevy *et al.*, 2019). Dog breeds were grouped into small,
148 medium, and large categories, as described by Posada *et al.* (2014).

149 *Quality characteristics of reports*

150 The quality characteristics of the reports were defined by compiling guidelines from the
151 International Council for Standardization in Hematology (Lee *et al.*, 2008), the Royal College
152 of Pathologists of Australasia (2014), and veterinary literature encompassing criteria for
153 evaluating and reporting BMA in dogs and cats (Abella-Bourgès *et al.*, 2005; Cowell and
154 Valenciano, 2023; Grindem *et al.*, 2002; Mylonakis and Hatzis, 2014; Raskin and Messick,
155 2012; Stacy and Harvey, 2017).

156 To ensure adherence to these criteria in the institution's issued report, it was determined that
157 the data must be included within the report itself, regardless of any additional information
158 provided in clinical history by the clinician requesting the bone marrow study. The variables
159 were categorized into two groups: basic and analytical.

160 Basic variables include essential information that should be present in the report regardless of
161 the bone marrow material. These include patient identification, details of the requesting
162 veterinarian detail, a summary of the patient's clinical history, specifics about the bone marrow
163 puncture, any observed presence of bone marrow particles or spicules, and a concluding
164 summary.

165 Analytical variables include aspects directly associated with the analysis of the obtained bone
166 marrow material. These variables include assessments of cellularity, differential counts,
167 morphological evaluations, and cellular indices.

168 *Frequency of diagnoses*

169 Reports were excluded if they lacked essential data for interpretation or if the sample quality
170 was compromised due to factors such as the absence of particles, hemodilution, mechanical
171 damage, or poor preservation. In this context, a diagnosis was construed as a judgment or
172 outcome derived from the comprehensive analysis of the sample's analysis, as documented in

173 each report by the professional responsible for the interpretation. This encompassed
174 consideration of both neoplastic and non-neoplastic conditions, as well as instances where no
175 abnormalities were detected, for estimating both relative and absolute frequencies.

176 *Factors associated with diagnoses*

177 Fisher's exact test was applied to compare the zoographic and clinical characteristics versus
178 diagnoses in BMA of the study population, using a significance level of $p < 0.05$. The analyses
179 were conducted using Jamovi® software version 2.3.

180 **Results**

181 A total of 139 veterinary centers across nineteen nationwide departments (25 municipalities)
182 were contacted. Of these, 32% (45/139) offered BMA collection, reading, or both. However,
183 half of these outsourced the service. Out of the remaining 22 institutions, eight agreed to
184 participate. Most of these were pathology laboratories that received samples from 46 veterinary
185 centers in capital municipalities of seven departments (Table 1).

186 **Table 1.** Distribution of BMA reports from dogs and cats by department in Colombia (2012
187 and 2023).

Department	Number of reports (%)
Antioquia	76 (56.3%)
Cundinamarca	1 (0.7%)
Valle del Cauca	16 (11.8%)
Atlántico	7 (5.1%)
Tolima	3 (2.2%)
Casanare	1 (0.7%)
Meta	13 (9.6%)
Missing	18 (13.3%)
Total	135 (100%)

188 A total of 135 BMA reports were obtained; 73.3% of these were reported between 2018 and
189 2023. There were 116 dogs and 19 cats, with an average age of 5.2 ± 3 -year-old (dogs $5.5 \pm$
190 3.2 , median 6; cats: 3.1 ± 3.0 , median 2), of which 53.3% were male.

191

192 **Table 2.** Hematological and clinical abnormalities reported in dogs and cats' consultations.

Abnormalities (n = 83)	n	%
Hematological (n = 75)		
Pancytopenia	13	17.3
Anemia and thrombocytopenia	13	17.3
Thrombocytopenia	11	14.7
Anemia	8	10.7
Anemia and leukocytosis	7	9.3
Anemia, thrombocytopenia, and leukocytosis	5	6.7
Leukopenia	5	6.7
Leukocytosis	5	6.7
Thrombocytopenia and leukopenia	4	5.3
Anemia and thrombocytosis	2	2.7
Anemia, thrombocytosis, and leukopenia	1	1.3
Thrombocytopenia and leukocytosis	1	1.3
History of infectious agents (n = 17)		
<i>Dogs</i>		
<i>Ehrlichia spp.</i>	3	17.6
<i>Anaplasma spp.</i>	3	17.6
<i>Ehrlichia spp.</i> and <i>Anaplasma spp.</i>	2	11.8
<i>Babesia spp.</i>	1	5.9
<i>Hepatozoon spp.</i>	1	5.9
<i>Mycoplasma spp.</i>	1	5.9
Missing	3	17.6
<i>Cats</i>		
<i>Mycoplasma spp.</i>	2	11.8
<i>Bartonella spp.</i>	1	5.9
Signs* (n = 41)		
Fever	11	26.8
Constitutional syndrome	21	51.2
Lymphadenopathy	5	12.2
Organomegaly	12	29.2

* One patient may be classified into multiple categories concurrently.

193 Among the patients with consultations (n = 83/135; 61.4%), 75/83 (90%) presented
 194 hematological alteration, 17/83 (20%) had a history of hemotropic agent infections and 41/83

195 (49%) reported clinical signs (Table 2). To a lesser extent, musculoskeletal abnormalities,
 196 respiratory signs, ascites, and petechiae were reported; blast cells were reported in three blood
 197 smears, and one cat was assessed positive for feline leukemia virus.

198 The aspirate samples were mostly taken from live patients 130/135 (96.3%), and the sample
 199 collection site was reported in only 36/135 (26.6%) cases. The sites included the sternum (n=1),
 200 femur (n=4), humerus (n=27), ilium (n=2), and tibia (n=2).

201 A total of 39 dog breeds were identified. The breeds with three or more individuals included
 202 Beagle, Golden Retriever, French Poodle, Labrador, German Shepherd, Shih Tzu, Springer
 203 Spaniel, Yorkshire Terrier, Schnauzer, Pinscher, Pitbull, and mixed breeds. In cats, nine breeds
 204 were identified: Bombay, British Shorthair, Domestic Shorthair, European Shorthair, Balinese,
 205 Russian Blue, Exotic, and Persian. However, 8/19 (42%) were mixed breeds. The distribution
 206 of dog breeds by size was small 22/116 (19%), medium 69/116 (59%), and large 24/116 (21%).
 207 Additionally, adults of both species were the most common age group (Table 3).

208 **Table 3.** Frequency of patients by species and age group (2012 and 2023).

Group		n	%
<i>Dogs (n = 116)</i>			
Puppy	(0 – 1-year-old)	8	6.9
Adult	(1 – 6-year-old)	59	50.8
Senior	(7 – 11-year-old)	38	32.7
Geriatric	(>12-year-old)	4	3.4
Missing		7	6.0
<i>Cats (n = 19)</i>			
Kitten/puppy	(0 – 1-year-old)	4	21.0
Young adult	(1 – 6-year-old)	12	63.1
Mature adult	(7 – 10-year-old)	2	10.5
Senior	(>10-year-old)	1	5.2

209

210 *Quality characteristics of reports*

211 The variables detailed in Tables 4 and 5 were analyzed to evaluate the quality of the reports.
 212 Among the fundamental elements comprising the header of a BMA report, two reports lacked
 213 data regarding the requesting physician or institution. However, all reports adequately
 214 identified the institution providing the service, including internal coding, specified sample type,
 215 and provided dates of receipt or result issuance, as well as the owner's name and the patient's

216 species. Notably, some reports omitted to record the name, age, sex, and breed of certain
 217 patients (Table 4).

218 Additionally, only 11/135 (8.1%) of the reports specified the puncture site for the aspirate.
 219 Relevant clinical data were missing in 115/135 (85.2%) of cases. Furthermore, the presence or
 220 absence of particles was not reported in 36/135 (26.7%) of cases, and 7/135 (5.2%) of reports
 221 lacked a conclusion (Table 4).

222 **Table 4.** Quality characteristics of dogs and cats BMA reports: basic variables.

Variable	Reported n = 135	
	Yes n (%)	No n (%)
Patient's name	133 (98.5)	2 (1.4)
Age	126 (93.3)	9 (6.7)
Sex	133 (98.5)	2 (1.5)
Breed	134 (99.3)	1 (0.7)
Requester information	133 (98.5)	2 (1.5)
Puncture site	11 (8.1)	124 (91.9)
Relevant clinical data	20 (14.8)	115 (85.2)
Presence of marrow particles	99 (73.3)	36 (26.7)
Conclusion or interpretation	128 (94.8)	7 (5.2)

223 Regarding the analytical variables, many reports were missing data on cellularity, differential
 224 count, morphological evaluation, and indices (Table 5). Out of the 104 reports where the
 225 differential count was reported, only 90 presented it in relative values. Furthermore, out of the
 226 85 reports where the total number of counted cells was reported, 18 had counts performed on
 227 fewer than 300 cells.

228 **Table 5.** Quality characteristics of dogs and cats BMA reports: analytical variables.

Variables of report	Reported (n = 135)		
	Yes n (%)	No n (%)	Not applicable n (%)
Cellularity	97 (71.9)	25 (18.5)	13 (9.6)
Differential count	104 (77.0)	18 (13.3)	13 (9.6)
Number of cells evaluated	85 (63.0)	37 (27.4)	13 (9.6)
Morphological assessment by cell line	50 (37.0)	71 (52.6)	14 (10.4)
Indices	95 (70.4)	17 (12.6)	23 (17.0)
Myeloid/erythroid Maturation	95 (100) 73 (76.8)	0 (0) 22 (23.2)	

229

230 *Diagnosis Frequency*

231 Out of the total BMA reports, 37/135 (27.4%) (4 from cats and 33 from dogs) were excluded
 232 due to sample quality issues. The diagnosis frequency was established for both species from
 233 the remaining 98/135 reports (72.6%). Neoplastic, hyperplastic, and hypoplastic groups were
 234 subclassified according to the affected cell line (Table 6). The male-to-female ratio was
 235 maintained, with 54/98 (55.1%) being males.

236 The most common diagnoses in dogs were erythroid, granulocytic, or combined hypoplasia,
 237 while neoplasia was more prevalent in cats. Infectious agents were identified as the sole
 238 alteration in five reports (Table 6). However, they were found in 16 BMA: *Anaplasma spp.* in
 239 three, *Ehrlichia spp.* in seven, *Babesia spp.* in two, *Hepatozoon spp.* in one, *Leishmania spp.*
 240 in one, and co-infection by *Anaplasma spp.* and *Ehrlichia spp.* in two cases. In three cases, the
 241 species of hemotropic reported in the BMA matched the initial consultation report. Likewise,
 242 in eight cases of hematopoietic tissue infections, patients presented with associated marrow
 243 alterations, including decreased cellularity, myelodysplasia, medullary aplasia, and hypoplasia,
 244 while three of these cases also exhibited hyperplasia and reactive bone marrow.

245

246 **Table 6.** Diagnosis frequency in dogs and cats BMA reports

Diagnostic	Dogs n=83		Cats n=15		Total n=98	
	n	%	n	%	n	%
<i>Hypoplasia</i>	30	36.1	1	6.7	31	31.6
Erythroid	7	23.3	0	0.0	7	22.6
Granulocytic	11	36.7	0	0.0	11	35.5
Erythroid and granulocytic	12	40.0	1	100.0	13	41.9
<i>Neoplasia</i>	14	16.8	6	40.0	20	20.4
Lymphoproliferative						
Acute	3	21.4	1	16.7	4	20.0
Chronic	3	21.4	1	16.7	4	20.0
Myeloproliferative						
Acute	1	7.1	2	33.3	3	15.0
Chronic	2	14.3	1	16.7	3	15.0
Myelodysplasia						
Granulocytic	4	28.6	1	16.7	5	25.0
Erythroid	1	7.1	0	0.0	1	5.0
<i>Hyperplasia</i>	13	15.7	4	26.4	17	17.3
Erythroid	3	23.1	3	75.0	6	35.3
Granulocytic	8	61.5	0	0.0	8	47.1
Granulocytic and erythroid	2	15.4	1	25.0	3	17.6
<i>Reactive Bone Marrow</i>	8	9.6	2	13.3	10	10.2
<i>Medullary Aplasia</i>	7	8.4	2	13.3	9	9.2
<i>Normal Bone Marrow</i>	6	7.2	0	0.0	6	6.1
<i>Infectious agents</i>	5	6.0	0	0.0	5	5.1

247 Chronic lymphoproliferative disorders included one case of plasma cell neoplasia in a dog,
248 while chronic myeloproliferative disorders reported chronic eosinophilic leukemia in a cat.
249 Myelodysplastic neoplasms detailed maturation changes in the nucleus and cytoplasm
250 exceeding 10%. Prussian blue staining for ring sideroblastic identification was not reported.

251 Among the five patients with lymphadenopathy, one was diagnosed with chronic
 252 myeloproliferative leukemia and two with acute lymphocytic leukemia.

253 *Factors associated with diagnoses*

254 Granulocytic hypoplasia was more common in females (9/44; 20.5%) than males (2/54; 3.7%;
 255 $p = 0.011$). However, neoplasms were more common in males (16/54; 29.6%) than in females
 256 (4/44; 9.1%; $p = 0.013$), and erythroid hyperplasia was only present in males (6/54; 11.1%; p
 257 $= 0.031$; Table 7). Hypoplasia occurred more frequently in dogs (30/83; 36.1%) than in cats
 258 (1/15; 6.7%; $p = 0.032$). However, erythroid hyperplasia was more common in cats (3/15;
 259 20.0%) than in dogs (3/83; 3.6%; $p = 0.044$). Granulocytic hyperplasia was more frequent in
 260 individuals of small breeds (4/13; 30.8%; $p = 0.013$). There was no breed predominance in cats
 261 for any diagnosis, as was the case when evaluating the disaggregated dog breeds. Four of the
 262 patients who presented with medullary aplasia had pancytopenia (4/9; 44.4%; $p = 0.002$). Other
 263 individuals with pancytopenia were diagnosed with hypoplasia, myelodysplasia, and *Ehrlichia*
 264 *spp.* infection.

265 **Table 7.** Factors associated with bone marrow diagnoses in dogs and cats from Colombia
 266 (2012-2023).

Factors	Diagnostic				p-value
	Yes		No		
	n	%	n	%	
Medullary Aplasia					
<i>Pancytopenia</i>					
Yes	4	44.4	5	55.6	0.002
No	3	5.7	50	94.3	
Granulocytic Hypoplasia					
<i>Sex</i>					
Female	9	20.5	35	79.5	0.011
Male	2	3.7	52	96.3	
Hypoplasia					
<i>Species</i>					
Dogs	30	36.1	53	63.9	0.032
Cats	1	6.7	14	93.3	
Hyperplasia erythroid					
<i>Species</i>					
Dogs	3	3.6	80	96.4	0.044
Cats	3	20.0	12	80.0	

<i>Sex</i>					
Female	0	0	44	100	0.031
Male	6	11.1	48	88.9	
Hyperplasia granulocytic					
<i>Breed</i>					
Small	4	30.8	9	69.2	0.013
Medium	2	3.8	51	96.2	
Large	2	12.5	14	87.5	
Neoplasia					
<i>Sex</i>					
Female	4	9.1	40	90.9	0.013
Male	16	29.6	38	70.4	

267

268 Discussion

269 The total number of BMA reports obtained during the study period from the eight institutions
 270 contrasts significantly with the findings described by Weiss (2006a, 2006b) and Turinelli *et al.*
 271 (2015, 2018). Weiss (2006a) compiled 203 samples from cats and 717 from dogs in a single
 272 American institution over eight years. Turinelli *et al.* (2015) gathered 295 dogs' samples over
 273 two years and 152 cats samples over three years in a European laboratory. These comparisons
 274 suggest that using BMA is less common in Colombia than in other countries. Similarly, these
 275 publications found that bone marrow evaluation is more frequent in dogs than in cats, consistent
 276 with the findings of this study, where the ratio of dogs to cats was 8:1. In Colombia, this
 277 disparity could be related to dogs being more common pets than cats (Ministerio de Salud y
 278 Protección Social, 2022). Additionally, considering that hematological alterations in cats are
 279 commonly associated with highly prevalent viral infections, it is possible that BMA is not
 280 routinely performed as a differential diagnostic technique (Molina, 2020; Ortega *et al.*, 2020;
 281 Santisteban *et al.*, 2021).

282 Persistent anemia, alone or accompanied by other abnormalities, was the most common
 283 indication for requesting the aspiration, followed by thrombocytopenia. These findings
 284 coincide with the study by Turinelli *et al.* (2015), where 37.6% of patients had persistent
 285 anemia. This hematological abnormality is a common finding in veterinary practice, with
 286 common causes including solid tumor cancer, hematopoietic cancer, inflammatory disease,
 287 immune-mediated disease, and renal damage (Chervier *et al.*, 2012; Grzelak and Fry, 2022).

288 Therefore, in cases of non-regenerative, persistent anemia of unknown cause, performing BMA
289 for differential diagnosis is crucial (Raskin and Messick, 2012).

290 Some of the data recorded in the result reports lacked information such as sex, age, consultation
291 history, description of particles, cellularity, morphological evaluation by cell line, and
292 differential count. These omissions hinder the correct interpretation of a BMA. Experts in
293 human hematopathology have demonstrated the advantages of implementing synoptic reports,
294 which gather basic and analytical elements while avoiding unstructured narrative reports (Sever
295 *et al.*, 2016). This approach facilitates the analysis of the results against established diagnostic
296 criteria, considering that the final report directly impacts the decision-making of the treating
297 physician (Mylonakis and Hatzis, 2014; Stacy and Harvey, 2017).

298 As previously described, sample quality is a well-known limiting factor in the analytical
299 process of BMA (Trejo-Ayala *et al.*, 2015). This study excluded 27.4% of samples due to
300 quality issues. This finding aligns with Turinelli *et al.*, (2015, 2018), where the percentage of
301 non-diagnostic samples in dogs and cats was 30.5% and 26.5%, respectively. However, these
302 findings differ from those reported by Weiss (2006a, 2006b), where the percentage of non-
303 diagnostic samples was 2.5% in cats and 1.6% in dogs. Hemodilution has been described as
304 the primary cause of rejection of aspirates, and deficiencies associated with this error are
305 improved with laboratory staff assistance in particle fishing or selection and extension (Riley
306 *et al.*, 2021). However, expertise in the sampling process lies exclusively with the clinician, as
307 demonstrated by Siddon *et al.* (2021).

308 The most frequent diagnosis in dogs was hypoplasia (36.1%), a rate closely aligned with
309 Girardi *et al.* in Brazil, with 26.2% in 65 dogs, considering that these were patients with
310 pancytopenia. This differs from the findings of this research compared to those reported by
311 Weiss (4.3%) and Turinelli *et al.* (7.8%) (Turinelli *et al.*, 2015; Weiss, 2006b). This group of
312 abnormalities has been linked to medication use, chemical substances, radiation, infections,
313 immune disorders, and neoplasms in both humans and animals (Grimes and Fry, 2015;
314 Javinsky, 2012; Moore *et al.*, 2023). In this study, a detailed investigation into the causes of
315 these abnormalities in patients was constrained by the lack of additional clinical history
316 information.

317 Moreover, hyperplasia ranked next, with a frequency of 15.7% in dogs, a value close to that
318 previously reported by other authors in patients treated in the United States (20.2%) and

319 European countries (25.1%) (Turinelli *et al.*, 2015; Weiss, 2006b). Non-neoplastic hyperplasia
320 must be correlated with clinical findings and diagnostic aids to determine the causes, as they
321 may be transient processes resulting from the medullary response to hemolytic anemias,
322 chronic inflammatory processes, or other factors (Haines *et al.*, 2022; Orazi *et al.* 2006).

323 Despite the small sample size, neoplasms were the most common diagnoses in cats. No specific
324 cell line predominated, resulting in similar proportions of lymphoproliferative,
325 myeloproliferative, and myelodysplastic disorders. For instance, Gilroy *et al.* (2011)
326 documented a case of chronic eosinophilic leukemia in a male cat exhibiting persistent
327 eosinophilia, mirroring findings in our study. Similarly, Campbell *et al.* (2013) reported 18
328 cases of chronic lymphocytic leukemia in cats over 10 years, while Patel *et al.* (2005) identified
329 16 cases of multiple myeloma in cats over eight years. Both studies applied diagnostic criteria
330 to both peripheral blood and bone marrow, revealing a considerable number of cases compared
331 to our study's findings over a longer period. This discrepancy underscores a potential
332 underdiagnosis of marrow conditions in dogs and cats.

333 Additionally, vector-borne diseases have been associated with various hematological
334 abnormalities, often manifesting as reductions in one or more cell lines (Bonilla-Aldana *et al.*,
335 2022; Tommasi *et al.*, 2014). This observation aligns with our study's results, where eight
336 patients with myelodysplasia, aplastic anemia, and hypoplasia showed evidence of *Ehrlichia*
337 *spp.*, *Babesia spp.*, and *Anaplasma spp.* in BMA, which were not previously detected in
338 peripheral blood samples.

339 A higher frequency of males was observed in the neoplasm group, which differs from the
340 findings of Turinelli *et al.* (2015, 2018), who reported similar sex ratios for malignancy. Other
341 studies in dogs have described a greater predisposition in males to various neoplasms; however,
342 specific records regarding sex predisposition to hematopoietic neoplasms were not found
343 (Pinello *et al.*, 2022). In a study conducted on 3400 dogs, it was found that males are diagnosed
344 with cancer at an earlier age than females (Rafalko *et al.*, 2023); however, in the present study,
345 no association between age and diagnosis was found, despite the majority of patients being in
346 the adult stage at the time of aspiration.

347 Nine cases were identified concerning the association between females and granulocytic
348 hypoplasia. It has been described that the bone marrow of dogs is highly susceptible to
349 suppression induced by endogenous or exogenous estrogens (Sontas *et al.*, 2009; Weiss, 2022).

350 However, complementary information was not available to identify treatments or underlying
351 conditions that may have favored the development of the disorder.

352 No publications discussing sexual predisposition in dogs or cats were found for erythroid
353 hyperplasia; for this study, all cases were males. This has been associated with peripheral
354 causes of cell destruction and myelodysplastic neoplasms (Haines *et al.*, 2022; Newman *et al.*,
355 2022; Weiss *et al.*, 2001).

356 In addition, alterations were reported in the megakaryocytic line, nor were there descriptions
357 of the use of BMAs in patient follow-up, lymphoma staging, or the application of molecular
358 biology techniques, cytogenetics, microbiological cultures, and immunophenotyping in any of
359 the reports as complementary studies for the final diagnosis. However, these techniques are
360 applied in veterinary medicine to define lineage and clonality and establish prognoses (Evans,
361 2023; Rout *et al.*, 2019). It should be noted that the availability of these tests is limited in
362 Colombia.

363 To our knowledge, this is the first publication on the characterization of BMA reports in dogs
364 and cats in the country. Thus, it is likely the first report on the frequency of diagnoses in BMAs
365 for both species. The study of BMA as a diagnostic tool in dogs and cats treated at participating
366 veterinary centers in Colombia is limited. The most reported diagnosis in dogs is hypoplasia,
367 while neoplasms were more frequent in cats, considering the number of individuals.

368 This study shows the need to adhere to the guidelines for the BMA report with the purpose of
369 improving diagnostic accuracy, shortening times, and avoiding reprocessing. Likewise, it is
370 necessary to improve the technique for obtaining and extending the sample, avoiding particle-
371 free and hemodiluted samples.

372 The use of BMA allowed us to diagnose and rule out central hematologic alterations in dogs
373 and cats with multiple clinical and laboratory findings. Moreover, this tool allows making
374 differential diagnoses in cases in which the BMA result is normal, concluding the peripheral
375 origin.

376 **Declarations**

377 *Funding*

378 The project did not receive any funding for its execution.

379 *Conflict of interest:*
380 The authors declare no conflicts of interest.

381 *Author contributions:*

382 Roldán-Carvajal: Project design, institution search, manuscript writing. Alzate-Velásquez:
383 Project design, institution search, manuscript editing. Muñoz-Duque: Project design, institution
384 search, manuscript editing. Mesa-Oquendo: Institution search, manuscript editing. Salazar-
385 Flórez: Statistical analysis, manuscript editing. Jaramillo-Arbeláez: Project design, manuscript
386 writing.

387 *Use of artificial intelligence (AI):*

388 No AI or AI-assisted technologies were used during the preparation of this work.

389

390 **References**

391 Abella-Bourgès N, Trumel C, Chabanne L, Diquélou A. Myélogramme et biopsie de moelle
392 osseuse. EMC - Vétérinaire 2005; 2(2): 74-95. <https://doi.org/10.1016/j.emcvet.2005.05.001>

393

394 Bonilla-Aldana DK, Gutiérrez-Grajales EJ, Osorio-Navia D, Chacón-Peña M, Trejos-Mendoza
395 AE, Pérez-Vargas S, Valencia-Mejía L, Marín-Arboleda LF, Martínez-Hidalgo JP, Reina-
396 Mora MA, González-Colonia LV, Cardona-Ospina JA, Jiménez-Posada EV, Diaz-Guio DA,
397 Salazar JC, Sierra M, Muñoz-Lara F, Zambrano LI, Ramírez-Vallejo E, Rodríguez-Morales
398 AJ. Haematological Alterations Associated with Selected Vector-Borne Infections and
399 Exposure in Dogs from Pereira, Risaralda, Colombia. Animals 2022; 12(24): 3460-3475.
400 <https://doi.org/10.3390/ani12243460>

401

402 Campbell MW, Hess PR, Williams LE. Chronic lymphocytic leukaemia in the cat: 18 cases
403 (2000-2010). Vet Comp Oncol 2013; 11(4): 256-264. [https://doi.org/10.1111/j.1476-
404 5829.2011.00315.x](https://doi.org/10.1111/j.1476-5829.2011.00315.x)

405

406 Chervier C, Cadoré JL, Rodriguez-Piñeiro MI, Deputte BL, Chabanne L. Causes of anaemia
407 other than acute blood loss and their clinical significance in dogs. J Small Anim Pract 2012;
408 53(4): 223-227. <https://doi.org/10.1111/j.1748-5827.2011.01191.x>

409

410 Comazzi S, Avery PR, Garden OA, Riondato F, Rütgen B, Vernau W. European canine
411 lymphoma network consensus recommendations for reporting flow cytometry in canine
412 hematopoietic neoplasms. *Cytometry Part B* 2017; 92(5): 411-419.
413 <https://doi.org/10.1002/cyto.b.21382>
414

415 Cowell RL, Valenciano AC, *Diagnóstico citológico y hematológico del perro y el gato*. España.
416 Elsevier 2023;5th ed.
417

418 Creevy KE, Grady J, Little SE, Moore GE, Strickler BG, Thompson S, Webb JA. 2019 AAHA
419 Canine Life Stage Guidelines. *J Am Anim Hosp Assoc* 2019; 55(6): 267-290.
420 <https://doi.org/10.5326/jaaha-ms-6999>
421

422 Evans SJM. Flow Cytometry in Veterinary Practice. *Vet Clin North Am Small Anim Pract*
423 2023; 53(1): 89-100. <https://doi.org/10.1016/j.cvsm.2022.07.008>
424

425 Gilroy C, Forzán M, Drew A, Vernau W. Eosinophilia in a cat with acute leukemia. *Can Vet J*
426 2011; 52(9): 1004-1008. [PMCID: PMC3157058](https://pubmed.ncbi.nlm.nih.gov/2157058/)
427

428 Girardi AF, Campos AN, Pescador CA, Almeida AD, Mendonça AJ, Nakazato L, Oliveira AC,
429 Sousa VR. Quantitative analysis of bone marrow in pancytopenic dogs. *Semina-ciencias*
430 *Agrarias* 2017; 38: 3639-3646. <https://doi.org/10.5433/1679-0359.2017v38n6p3639>
431

432 Grimes CN, Fry MM. Nonregenerative Anemia: Mechanisms of Decreased or Ineffective
433 Erythropoiesis. *Veterinary Pathology* 2015; 52(2): 298-311.
434 <https://doi.org/10.1177/0300985814529315>
435

436 Grindem CB, Neel JA, Juopperi TA. Cytology of bone marrow. *Vet Clin North Am Small*
437 *Anim Pract* 2002; 32(6): 1313-1374. [https://doi.org/10.1016/s0195-5616\(02\)00052-9](https://doi.org/10.1016/s0195-5616(02)00052-9)
438

439 Grzelak AK, Fry MM. Anemia of Inflammatory, Neoplastic, Renal, and Endocrine Diseases.
440 In: Brooks MB, Harr KE, Seelig DM, Wardrop KJ, Weiss DJ, editors. *Schalm's Veterinary*
441 *Hematology* 7th ed. Nueva Jersey: Wiley-Blackwell. 2022; p. 313-317.
442 <https://doi.org/https://doi.org/10.1002/9781119500537.ch39>
443

444 Haines JM, Mackin A, Day MJ. Immune-Mediated Anemia in the Dog. In: Brooks MB, Harr
445 KE, Seelig DM, Wardrop KJ, Weiss DJ, editors. Schalm's Veterinary Hematology 7th ed.
446 Nueva Jersey: Wiley-Blackwell 2022; p. 278-291.
447 <https://doi.org/10.1002/9781119500537.ch35>
448
449 Hawkins R. Managing the pre- and post-analytical phases of the total testing process. Ann Lab
450 Med 2012; 32(1): 5-16. <https://doi.org/10.3343/alm.2012.32.1.5>
451
452 Javinsky E. Hematology and Immune-Related Disorders. In: Little SE, editor. The Cat: Clinical
453 Medicine and Management 2nd ed. Georgia: Elsevier Saunders 2012; p. 643-703.
454 <https://doi.org/10.1016/B978-1-4377-0660-4.00025-9>
455
456 Lee SH, Erber WN, Porwit A, Tomonaga, M, Peterson LC. ICSH guidelines for the
457 standardization of bone marrow specimens and reports. Int J Lab Hematol 2008; 30(5): 349-
458 364. <https://doi.org/10.1111/j.1751-553X.2008.01100.x>
459
460 Messick JB. A Primer for the Evaluation of Bone Marrow. Vet Clin North Am Small Anim
461 Pract 2023; 53(1): 241-263. <https://doi.org/10.1016/j.cvsm.2022.08.002>
462
463 Ministerio de Salud y Protección Social. Cobertura Vacunación antirrábica de perros y gatos
464 por departamento y municipio. Colombia: biblioteca digital. 2022.
465 <https://www.minsalud.gov.co/BibliotecaDigital/vacunacion-antirrabica-perros-gatos2022>
466
467 Molina V. Prevalence of the Feline Leukemia Virus (FeLV) in Southern Valle de Aburrá,
468 Colombia. Rev Med Vet 2020; 40: 9-16. <https://doi.org/10.19052/mv.vol1.iss40.2>
469
470 Moore C, Krishnan K. Bone Marrow Failure. StatPearls [Internet] 2023.
471 <https://www.ncbi.nlm.nih.gov/books/NBK459249/>
472
473 Mylonakis M, Hatzis A. Practical bone marrow cytology in the dog and cat. J Hellenic Vet
474 Med Soc 2014; 65(3): 181-196. <https://doi.org/10.12681/jhvms.15534>
475

476 Newman A, Stokol T. Immune-Mediated Anemia in the Cat. In: Brooks MB, Harr KE, Seelig
477 DM, Wardrop KJ, Weiss DJ, editors. Schalm's Veterinary Hematology 7th ed. Nueva Jersey:
478 Wiley-Blackwell 2022; p. 292-299. <https://doi.org/10.1002/9781119500537.ch36>
479

480 Orazi A, O'Malley DP, Arber DA. The hyperplasias. In Orazi A, Arber DA, O'Malley DP,
481 editors. Illustrated Pathology of the Bone Marrow 1st ed. Cambridge: Cambridge University
482 Press 2006; p. 31-38. <https://doi.org/10.1017/CBO9780511543531>
483

484 Ortega C, Valencia AC, Duque-Valencia J, Ruiz-Saenz J. Prevalence and Genomic Diversity
485 of Feline Leukemia Virus in Privately Owned and Shelter Cats in Aburrá Valley, Colombia.
486 Viruses 2020; 12(4); 464-477. <https://doi.org/10.3390/v12040464>
487

488 Patel RT, Caceres A, French AF, McManus PM. Multiple myeloma in 16 cats: a retrospective
489 study. Vet Clin Pathol 2005; 34(4): 341-352. [https://doi.org/https://doi.org/10.1111/j.1939-](https://doi.org/https://doi.org/10.1111/j.1939-165X.2005.tb00059.x)
490 [165X.2005.tb00059.x](https://doi.org/https://doi.org/10.1111/j.1939-165X.2005.tb00059.x)
491

492 Pinello K, Pires I, Castro AF, Carvalho PT, Santos A, de Matos A, Queiroga F, Canadas-Sousa
493 A, Dias-Pereira P, Catarino J, Faísca P, Branco S, Lopes C, Marcos F, Peleteiro MC, Pissarra
494 H, Ruivo P, Magalhães R, Severo M, Niza-Ribeiro J. Cross Species Analysis and Comparison
495 of Tumors in Dogs and Cats, by Age, Sex, Topography and Main Morphologies. Data from
496 Vet-OncoNet. Vet. Sci 2022; 9(4): 167-185. <https://doi.org/10.3390/vetsci9040167>
497

498 Posada O S, Gomez OL, Rosero NR. Application of the logistic model to describe the growth
499 curve in dogs of different breeds. Rev MVZ Córdoba 2014; 19: 4015-4022.
500 <https://doi.org/10.21897/rmvz.121>
501

502 Rafalko JM, Kruglyak KM, McCleary-Wheeler AL, Goyal V, Phelps-Dunn A, Wong LK,
503 Warren CD, Brandstetter G, Rosentel MC, DiMarzio L, McLennan LM, O'Kell AL, Cohen
504 TA, Grosu DS, Chibuk J, Tsui DWY, Chorny I, Flory A. Age at cancer diagnosis by breed,
505 weight, sex, and cancer type in a cohort of more than 3,000 dogs: Determining the optimal age
506 to initiate cancer screening in canine patients. PLoS One 2023; 18(2): e0280795.
507 <https://doi.org/10.1371/journal.pone.0280795>
508

509 Raskin RE, Messick JB. Bone marrow cytologic and histologic biopsies: indications,
510 technique, and evaluation. *Vet Clin North Am Small Anim Pract* 2012; 42(1): 23-42.
511 <https://doi.org/10.1016/j.cvsm.2011.10.001>
512

513 Riley RS, Gandhi P, Harley SE, Garcia P, Dalton JB, Chesney A. A Synoptic Reporting System
514 to Monitor Bone Marrow Aspirate and Biopsy Quality. *J Pathol Inform* 2021; 12: 23-29.
515 https://doi.org/10.4103/jpi.jpi_53_20
516

517 Ritt MG. Epidemiology of Hematopoietic Neoplasia. In: Brooks MB, Harr KE, Seelig DM,
518 Wardrop KJ, Weiss DJ, editors. *Schalm's Veterinary Hematology 7th ed.* Nueva Jersey: Wiley-
519 Blackwell; 2022. p. 457-462. <https://doi.org/10.1002/9781119500537.ch58>
520

521 Rout ED, Burnett RC, Yoshimoto JA, Avery PR, Avery AC. Assessment of immunoglobulin
522 heavy chain, immunoglobulin light chain, and T-cell receptor clonality testing in the diagnosis
523 of feline lymphoid neoplasia. *Vet Clin Pathol* 2019; 48(S1): 45-58.
524 <https://doi.org/https://doi.org/10.1111/vcp.12767>
525

526 Rütgen BC, Bouschor J. Classification and General Features of Lymphoma and Leukemia. In:
527 Brooks MB, Harr KE, Seelig DM, Wardrop KJ, Weiss DJ, editors. *Schalm's Veterinary*
528 *Hematology 7th ed.* Nueva Jersey: Wiley-Blackwell; 2022;p. 528-537.
529 <https://doi.org/10.1002/9781119500537.ch65>
530

531 Santisteban RR, Muñoz-Rodríguez LC, Díaz Nieto J, Pachón-Londoño V, Curiel-Peña J.
532 Seroprevalencia del virus de inmunodeficiencia felina (VIF) y el virus de la leucemia felina
533 (ViLeF) en gatos del centro de Risaralda, Colombia. *Rev Inv Vet Perú* 2021; 32(3): e18901.
534 <https://doi.org/10.15381/rivep.v32i3.18901>
535

536 Sciacovelli L, Aita A, Padoan A, Pelloso M, Antonelli G, Piva E, Chiozza ML, Plebani M.
537 Performance criteria and quality indicators for the post-analytical phase. *Clin Chem Lab Med*
538 2016; 54(7): 1169-1176. <https://doi.org/10.1515/cclm-2015-0897>
539

540 Sever C, Abbott CL, de Baca ME, Khoury JD, Perkins SL, Reichard KK, Taylor A, Terebelo
541 HR, Colasacco C, Rumble RB, Thomas NE. Bone Marrow Synoptic Reporting for
542 Hematologic Neoplasms: Guideline From the College of American Pathologists Pathology and

543 Laboratory Quality Center. Arch Pathol Lab Med 2016; 140(9): 932-949.
544 <https://doi.org/10.5858/arpa.2015-0450-SA>
545
546 Siddon AJ, Kroft SH. The Lab as a Driver of Quality in the Preanalytical Realm: The Case of
547 Technologist-Assisted Bone Marrow Biopsies. Am J Clin Pathol 2021; 157(4): 480-481.
548 <https://doi.org/10.1093/ajcp/aqab180>
549
550 Sontas HB, Dokuzeylu B, Turna O, Ekici H. Estrogen-induced myelotoxicity in dogs: A
551 review. Can Vet J 2009; 50(10): 1054-1058. [PMCID: PMC2748286](https://pubmed.ncbi.nlm.nih.gov/2748286/)
552
553 Stacy NI, Harvey JW. Bone marrow aspirate evaluation. Vet Clin North Am Small Anim Pract
554 2017; 47(1): 31-52. <https://doi.org/10.1016/j.cvsm.2016.07.003>
555
556 Tommasi ASD, Baneth G, Breitschwerdt EB, Stanneck D, Dantas-Torres F, Otranto D,
557 Caprariis D. Anaplasma platys in Bone Marrow Megakaryocytes of Young Dogs. J Clin
558 Microbiol 2014; 52(6): 2231-2234. [https://doi.org/doi:10.1128/jcm.00395-14](https://doi.org/10.1128/jcm.00395-14)
559
560 Turinelli V, Gavazza A, Stock G, Fournel-Fleury C. Canine bone marrow cytological
561 examination, classification, and reference values: A retrospective study of 295 cases. Res Vet
562 Sci 2015; 103: 224-230. <https://doi.org/10.1016/j.rvsc.2015.10.008>
563
564 Turinelli V, Gavazza A. Retrospective study of 152 feline cytological bone marrow
565 examinations: preliminary classification and ranges. J Feline Med Surg 2018; 20(12): 1158-
566 1168. <https://doi.org/10.1177/1098612x18757602>
567
568 The Royal College of Pathologists of Australasia. Bone marrow specimen (aspirate and
569 trephine biopsy) structured reporting protocol. 1st ed. RCPA. 2014. [ISBN: 978-1-74187-964-3](https://doi.org/10.1177/1098612x18757602)
570 [3](https://doi.org/10.1177/1098612x18757602)
571
572 Trejo-Ayala RA, Luna-Pérez M, Gutiérrez-Romero M, Collazo-Jaloma J, Cedillo-Pérez MC,
573 Ramos-Peñafiel CO. Bone marrow aspiration and biopsy. Technique and considerations. Rev
574 Med Hosp Gen Méx 2015; 78(4): 196-201. <https://doi.org/10.1016/j.hgmx.2015.06.006>
575

576 Weiss DJ, Aird B. Cytologic Evaluation of Primary and Secondary Myelodysplastic
577 Syndromes in the Dog. *Vet Clin Pathol* 2001; 30(2): 67-75.
578 <https://doi.org/https://doi.org/10.1111/j.1939-165X.2001.tb00261.x>
579
580 Weiss DJ. A retrospective study of the incidence and classification of bone marrow disorder in
581 cats (1996–2004). *Comp Clin Path* 2006a; 14: 179-185. [http://dx.doi.org/10.1007/s00580-005-](http://dx.doi.org/10.1007/s00580-005-0575-1)
582 [0575-1](http://dx.doi.org/10.1007/s00580-005-0575-1)
583
584 Weiss DJ. A retrospective study of the incidence and the classification of bone marrow
585 disorders in the dog at a veterinary teaching hospital (1996–2004). *J Vet Intern* 2006b; 20(4):
586 955-961. <https://doi.org/10.1111/j.1939-1676.2006.tb01811.x>
587
588 Weiss DJ. Blood and Bone Marrow Toxicity Induced by Drugs, Heavy Metals, Chemicals, and
589 Toxic Plants. In: Brooks MB, Harr KE, Seelig DM, Wardrop KJ, Weiss DJ, editors. *Schalm's*
590 *Veterinary Hematology* 7th ed. Nueva Jersey: Wiley-Blackwell 2022; p. 122-132.
591 <https://doi.org/10.1002/9781119500537.ch15>
592
593 Woods GA, Simpson M, Boag A, Paris J, Piccinelli C, Breheny C. Complications associated
594 with bone marrow sampling in dogs and cats. *J Small Anim Pract* 2021; 62(3): 209-215.
595 <https://doi.org/10.1111/jsap.13274>